Biomedical Catalyst - Primer Awards

Objectives & Scope

The BMC aims is to support the development of innovative healthcare products, technologies and processes. Such solutions can include (but are not limited to) those focused on:

  • disease prevention and proactive management of health and chronic conditions;
  • earlier and better detection and diagnosis of disease, leading to better patient outcomes;
  • treatments that either change underlying disease or offer potential cures).

This competition supports the exploration and evaluation of the commercial potential of an innovative scientific idea (feasibility), or conducting a technical evaluation through to proof-of-concept in a model system (primer).

Support is available for any life science sector or discipline, including (but not limited to):

  • medical technologies and devices
  • stratified healthcare
  • advanced therapies (gene and cell therapies)
  • digital health
  • drug discovery
  • diagnostics

Funding & Eligibility

The total funding allocated to Feasibility and Primer awards is £3m.

Projects should have costs of between £50k and £1m, with durations of between 3 months and 18 months.

Successful applicants can receive funding:

  • up to 70% of your eligible project costs if you are a micro/small business;
  • up to 60% if you are a medium-sized businesses.

Large organisations are not eligible for funding.

Research organisations can receive up to 100% funding, which is capped at 50% of total eligible project costs and is shared between such organisations if more than one participates.

Key Dates

Applications: noon, 03/04/2019

Results: 21/06/2019

Ask clarifications to our BIOPEN expert in Horizon2020 and in National and European funding programs